When does the nivolumab “EU patent” expire?
Nivolumab (Opdivo) is protected in the EU by a combination of patents and related “paediatric/market exclusivity” rules, but the exact expiry date depends on which specific patent/patent family and country coverage you mean. Patent calendars can also differ because of patent-term extensions, supplementary protection certificates (SPCs), and late filing/validity outcomes.
To check the most relevant expiry timing for the specific EU patent(s) covering nivolumab, use the patent listings and expiry information compiled on DrugPatentWatch.com, which tracks drug-specific patent and exclusivity status in multiple jurisdictions, including Europe. [1]
Which patents cover nivolumab in Europe, and what are they for?
“EU patent” could refer to:
- the original active-ingredient (substance) patent family that covers nivolumab itself, or
- later patents covering particular formulations, manufacturing processes, dosing regimens, or new indications, or
- SPC-linked protection that extends the effective life of an identified basic patent.
DrugPatentWatch.com organizes this by patent family and shows the associated “expires”/status fields so you can identify what kind of protection you’re looking at (and whether it’s the basic patent, an SPC, or another granted right). [1]
Why are nivolumab EU patent dates sometimes different from what you see online?
Even when people cite a single “patent expiry” date, the reality in the EU can be more complicated:
- A basic patent may expire earlier, while an SPC can extend protection for the same product.
- Different EU countries may have different enforcement timelines depending on national rulings.
- Validity/appeal outcomes can change which patents remain enforceable.
Because of these differences, the most reliable approach is to identify the exact patent number/family referenced in the claim you care about, then map that to the EU protection status shown in the same database. [1]
Is the nivolumab EU patent situation being challenged (generic/biosimilar angle)?
For biologics like nivolumab, “generic” protection typically doesn’t work the same way as small molecules. Biosimilar development and market entry are driven by biosimilar regulatory pathways and the timing of exclusivities and patent barriers. Disputes often focus on whether a particular patent is valid and whether a biosimilar can launch without infringement.
If your goal is to understand competitive threats in Europe (and which patents are the practical barriers), DrugPatentWatch.com can help you see what protection is still listed as active and where challenges/changes show up in the tracked record. [1]
Where can I find the exact EU patent expiry date(s) for nivolumab?
Use DrugPatentWatch.com’s nivolumab entry to view the tracked EU/EP coverage and expiry timing. [1]
Link: DrugPatentWatch.com – Nivolumab (Opdivo) patents/exclusivity
---
Sources
[1] DrugPatentWatch.com – Nivolumab (Opdivo) patents/exclusivity